

#38645

DATE: MARCH 22, 2016

SUBJECT: CELLADON CORPORATION – REVERSE SPLIT AND

NAME/SYMBOL/CUSIP CHANGE

OPTION SYMBOL: CLDN NEW SYMBOL: EIGR1

DATE: 3/23/16

Celladon Corporation (CLDN) has announced a 1-for-15 reverse stock split and a name, trading symbol, and CUSIP change. As a result of the reverse stock split and name/symbol/CUSIP change, each CLDN Common Share will be converted into the right to receive approximately 0.066667 (New) Eiger BioPharmaceuticals, Inc. (EIGR) Common Shares (CUSIP 28249U105). The reverse stock split and name/symbol/CUSIP change will become effective before the market open on March 23, 2016. Cash will be paid in lieu of fractional EIGR shares.

CONTRACT ADJUSTMENT

Effective Date: March 23, 2016

Option Symbol: CLDN changes to EIGR1

Contract

Multiplier: 1

Strike Divisor: 1

New Multiplier: 100 (e.g., for premium or strike dollar extensions 1.00 will equal \$100)

New Deliverable

Per Contract: 1) 6 (New) Eiger BioPharmaceuticals, Inc. (EIGR) Common Shares

2) Cash in lieu of approximately 0.6667 fractional EIGR Shares

CUSIP: EIGR (New): 28249U105

PRICING

Until the cash in lieu amount is determined, the underlying price for EIGR1 will be determined as follows:

EIGR1 = 0.066667 (EIGR)

DELAYED SETTLEMENT

The EIGR component of the EIGR1 deliverable will settle through National Securities Clearing Corporation (NSCC). OCC will delay settlement of the cash portion of the EIGR1 deliverable until the cash in lieu of fractional EIGR Shares is determined. Upon determination of the cash in lieu amount, OCC will require Put exercisers and Call assignees to deliver the appropriate cash amount.

DISCLAIMER

This Information Memo provides an unofficial summary of the terms of corporate events affecting listed options or futures prepared for the convenience of market participants. OCC accepts no responsibility for the accuracy or completeness of the summary, particularly for information which may be relevant to investment decisions. Option or futures investors should independently ascertain and evaluate all information concerning this corporate event(s).

The determination to adjust options and the nature of any adjustment is made by a panel of The OCC Securities Committee pursuant to OCC By-Laws, Article VI, Sections 11 and 11A. The adjustment panel is comprised of representatives from OCC and each exchange which trades the affected option. The determination to adjust futures and the nature of any adjustment is made by OCC pursuant to OCC By-Laws, Article XII, Sections 3, 25, or 25A, as applicable. For both options and futures, each adjustment decision is made on a case by case basis. Adjustment decisions are based on information available at the time and are subject to change as additional information becomes available or if there are material changes to the terms of the corporate event(s) occasioning the adjustment.

ALL CLEARING MEMBERS ARE REQUESTED TO IMMEDIATELY ADVISE ALL BRANCH OFFICES AND CORRESPONDENTS ON THE ABOVE.

For questions regarding this memo, call Investor Services at 1-888-678-4667 or email investorservices@theocc.com. Clearing Members may contact Member Services at 1-800-544-6091 or, within Canada, at 1-800-424-7320, or email memberservices@theocc.com.